Consent given pursuant to sections 14 and 14A to the importation and supply of the therapeutic goods specified by Pfizer Australia

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was established to regulate the importation, supply, and advertising of therapeutic goods, including medicines, medical devices, and blood. This legislation was introduced to address the need for a comprehensive regulatory framework that ensures the safety, quality, and efficacy of therapeutic goods available to consumers. In certain cases, the Act allows for flexibility through mechanisms such as consents to address non-conformance issues with specific products. For instance, under Section 14 and 14A, the Secretary of the Department of Health can grant consent for the importation and supply of therapeutic goods that do not fully comply with certain regulatory requirements, provided specific conditions are met. The policy objective here is to balance the need for regulatory compliance with the practicalities of product supply and consumer safety, ensuring that therapeutic goods meet essential standards without undue disruption to availability.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, providing a framework for their manufacture, importation, supply, and advertising. This Act applies to all therapeutic goods, including medicines, medical devices, and blood and blood components, and it is enforced by the Therapeutic Goods Administration (TGA). The Act applies to entities and individuals involved in the supply or advertising of these goods within Australia, encompassing both domestic and international supply chains. The jurisdictional reach of the Act is national, extending across all states and territories of Australia. Specific exclusions or exemptions within the Act are generally defined through subordinate instruments such as the Therapeutic Goods Regulations, which provide detailed specifications and requirements for various therapeutic goods categories. In the context of the recent consent granted by the delegate of the Secretary, this allows for temporary flexibility in compliance with labelling requirements for specific pharmaceutical products, demonstrating the Act’s ability to adapt through subordinate instruments to address particular circumstances while maintaining overarching regulatory standards.

Key Provisions

The Therapeutic Goods Act 1989, specifically sections 14 and 14A, provides the framework under which the Secretary of the Department of Health can give consent for the importation and supply of therapeutic goods that do not conform to certain labelling requirements. In this instance, Pfizer Australia Pty Ltd applied for and was granted consent to supply specific dosages of sildenafil (VIAGRA) that do not conform to the labelling requirements stipulated in paragraph 3(2)(h) and 3(2)(i) of the Therapeutic Goods Order No. 69. This consent allows for the importation and supply of sildenafil (as citrate) 25 mg, 50 mg, and 100 mg tablet blister packs, which lack the necessary batch number and expiry date prefixes on the foil blister labels. This consent is specifically for the period from 16 June 2015 until 31 October 2015. Under this legislation, Pfizer Australia Pty Ltd is obligated to comply with several conditions as part of the consent granted by the Secretary. Firstly, the consent applies only to the currently approved foil blister labels that do not include the batch number and expiry date prefixes. Secondly, Pfizer must provide a 'Dear Pharmacist' letter, identical to the one provided to the Therapeutic Goods Administration on 16 June 2015, with each batch of the affected products. This letter is intended to advise pharmacists to remind patients to keep the blister packs with the correctly labelled carton. These obligations are crucial to ensuring that the non-conformity with the labelling requirements does not compromise the safety or efficacy of the therapeutic goods being supplied. Failure to comply with the conditions of the consent or the requirements of the Therapeutic Goods Act 1989 may result in both civil and criminal consequences. The specific offences and penalties are not detailed in the Gazette entry, but under the broader provisions of the Act, breaches can lead to fines, imprisonment, or both, depending on the severity of the non-compliance. The Therapeutic Goods Act 1989 provides for substantial penalties to ensure adherence to the regulatory framework governing therapeutic goods in Australia, thereby protecting public health and safety.